Navigation Links
Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Date:12/17/2007

Presentations Provide New Insights into Treatment Impact, Node-Positive

Breast Cancer, Measuring ER/PR Scores

REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies reinforcing the clinical utility of the company's Oncotype DX(R), a multi-gene expression test to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. This research was presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-15.

"The extensive body of research on Oncotype DX, including data presented in San Antonio this week, along with its recent inclusion in ASCO treatment guidelines, supports the use of Oncotype DX in treatment planning for women with early-stage estrogen receptor-positive breast cancer," said Lori J. Goldstein, M.D., Director of the Breast Evaluation Center at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and author of two Oncotype DX studies.

Eight studies presented at the San Antonio Breast Cancer Symposium evaluated Oncotype DX, including its use in estrogen receptor-positive, node- positive breast cancer; the test's impact on treatment selection and patient satisfaction; reporting of quantitative ER and PR scores within the Oncotype DX report; and a comparison between the Oncotype DX Recurrence Score(TM) and Adjuvant Online, among other presentations.

Positive Results in Node-Positive Disease

* An oral presentation by the Southwest Oncology Group (SWOG) on

Thursday, December 13 reported positive results for the Oncotype DX

Recurrence Score result in early-stage estrogen receptor
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 Zynerba Pharmaceuticals ... development of innovative transdermal synthetic cannabinoid treatments, today announced ... 26th Annual Healthcare Conference 2014. The conference will be ... Palace in New York . Zynerba,s ... at 4:50 pm on Tuesday, December 2. ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... UCB and Harvard University officially launched their innovative Research ... Boston last night in the presence of his Royal ... http://photos.prnewswire.com/prnh/20110630/NY28450 ) The Alliance creates a ... Harvard scientists continuing their research that holds potential for ...
... announces that a new market research report is ... Devices & Diagnostics Equipments in India ... the Indian Medical Devices & equipments market is ... annually. India is growing as a ...
Cached Medicine Technology:UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3Medical Devices & Diagnostics Equipments in India 2Medical Devices & Diagnostics Equipments in India 3Medical Devices & Diagnostics Equipments in India 4Medical Devices & Diagnostics Equipments in India 5
(Date:11/28/2014)... November 28, 2014 Nipomo Family ... Christina Do, recently opened its doors at 195 N. ... Along with preventative care like teeth cleanings, oral exams, ... dentistry, Invisalign, teeth whitening (and Kor whitening), laser whitening, ... addition, Nipomo Family Dentistry’s five-person team also takes a ...
(Date:11/27/2014)... One of the major segments of ... implant dentistry comprises dental implants and abutments as ... dental care is bifurcated into two segments: dental ... is composed of large equipment. , View full ... , The worldwide dental market is growing ...
(Date:11/27/2014)... The report “Blepharitis – Pipeline ... therapeutic development for Blepharitis, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Blepharitis and special features on late-stage and discontinued ...
(Date:11/27/2014)... Petersburg, Fl (PRWEB) November 28, 2014 Let ... , Beautiful Christmas boxes with bows on top, filled with ... All prices are deeply discounted today while quantities last - ... . , All products are also available on Amazon at ... found on each Sublime shop product page for ease. , ...
(Date:11/27/2014)... 27, 2014 In a world ... to sleep has lessened, and due to the ... quality of sleep has eroded. According to Web ... the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably ... by an incalculable amount, leading not only to ...
Breaking Medicine News(10 mins):Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 2Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 3Health News:Blepharitis Pipeline Market Review on Drugs and Companies H2 2014 4Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... , SATURDAY, May 21 (HealthDay News) -- As summer ... heat-related illnesses, experts say. "We are not invincible ... Brendon McDermott, an athletic trainer with the University of ... Institute (KSI) Medical and Science Advisory Board, in a ...
... (May 20, 2011)The American Federation for Aging Research (AFAR) today ... fellows and junior faculty at 27 Centers of Excellence in ... funded with support from the John A. Hartford Foundation, has ... cadre of academic leaders in geriatrics. As our nation ages, ...
... discs in the low back wear out, become compressed and ... discs can be a viable alternative to standard fusion surgery, ... recently published in the Journal of Bone and Joint ... fusion but this is believed the first to evaluate the ...
... are treated for cancer during childhood have a significantly higher ... severe later in life, according to a study led ... the need for childhood cancer survivors and their physicians to ... health care needs are met. "We have, in a ...
... , FRIDAY, May 20 (HealthDay News) -- The number of ... in recent years, a new government study shows. Researchers ... data from birth certificates for more than 4 million live ... previous years. The investigators found that 28,357 babies were ...
... of UT Dallas is known throughout the world for his ... at The University of Texas at Dallas, he,s known to ... received the President,s Teaching Excellence Award for Tenure-Track Faculty during ... from among more than 100 eligible faculty members who were ...
Cached Medicine News:Health News:Keeping Cool in the Heat 2Health News:AFAR announces the 2011 Hartford Scholars in Geriatric Medicine 2Health News:2-year results: Artificial disc a viable alternative to fusion for 2-level disc disease 2Health News:Childhood cancer survivors at higher risk for future GI complications 2Health News:Home Births Jump 20 Percent in 4 Years: U.S. Report 2Health News:Home Births Jump 20 Percent in 4 Years: U.S. Report 3Health News:UT Dallas' Moller receives teaching award 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: